In 2025, SCHOTT Pharma AG & Co completed a corporate carbon footprint assessment and publicly disclosed its greenhouse gas (GHG) emissions according to the GHG Protocol, covering Scope 1 (direct emissions from owned or controlled sources), Scope 2 (indirect emissions from purchased energy) and Scope 3 (indirect emissions across the value chain).
SCHOTT Pharma AG & Co has also provided a category-level breakdown for 12 out of 15 Scope 3 emissions categories, offering greater transparency into its value chain emissions.
| Metric (tCO2e) | 2025 | 2024 | 2023 | 2022-2019 |
|---|---|---|---|---|
Total Scope 1 | 29,773a | 27,536a | 30,226b | |
Total Scope 2 | ||||
Market-Based | 0a | 60a | 0b | |
Location-Based | 44,596a | 43,941a | 43,587b | |
Total Scope 3 | 412,948a | 397,719a | 418,000b | |
Total Scope 1 Revenue Intensity (tCO2e/$M) | 25.7303a | 25.7574a | 31.8455b |
You are welcome to quote or reference individual data points from this page, provided you include the following attribution with a visible, clickable link to this page: "Source: Tracenable, the global reference for ESG data"
Bulk collection, scraping, resale, or redistribution of data across multiple company profiles is not permitted without our prior written permission. For more information, see our General Terms and Conditions.
Every figure on this dashboard has a transparent audit trail. With Tracenable, each data point is traceable back to its original source, viewable directly inside our platform.
In 2025, the total operational greenhouse gas (GHG) emissions of SCHOTT Pharma AG & Co amounted to 74,369 metric tons of CO2 equivalent. This figure includes both direct emissions from owned or controlled sources (Scope 1) and indirect emissions from purchased energy (Scope 2).a
Compared to 2024, the total operational greenhouse gas (GHG) emissions of SCHOTT Pharma AG & Co increased by 4.05%, suggesting that the company faced challenges in reducing its emissions from its core operations.a
In 2025, the total Scope 1 emissions of SCHOTT Pharma AG & Co were 29,773 metric tons of CO₂ equivalent (tCO₂e).a
Since 2023, SCHOTT Pharma AG & Co's Scope 1 emissions have decreased by 1.5%, reflecting a declining long-term trend in Scope 1 emissions over time.ab
Compared to the previous year (2024), SCHOTT Pharma AG & Co's Scope 1 emissions increased by 8.12%, suggesting that the company faced challenges in reducing emissions from its directly owned or controlled operations.a
In 2025, SCHOTT Pharma AG & Co reported Scope 2 greenhouse gas (GHG) emissions of 0 tCO₂e using the market-based method and 44,596 tCO₂e using the location-based method.a
Since 2023, SCHOTT Pharma AG & Co's Scope 2 greenhouse gas (GHG) emissions (Location-Based) have remained relatively stable, indicating that SCHOTT Pharma AG & Co's emissions have plateaued with no significant change in its energy consumption footprint.ab
Compared to the previous year (2024), SCHOTT Pharma AG & Co's Scope 2 emissions (Location-Based) have remained relatively stable, indicating that SCHOTT Pharma AG & Co's emissions have plateaued with no significant change in its energy consumption footprint.a
In 2025, SCHOTT Pharma AG & Co reported its Scope 2 emissions using the market-based method and using the location-based method.a
In 2025, SCHOTT Pharma AG & Co reported 412,948 metric tons of CO₂ equivalent (tCO₂e) of Scope 3 greenhouse gas (GHG) emissions, representing indirect emissions across its upstream and downstream value chain.a
The 2025 disclosure of SCHOTT Pharma AG & Co includes a breakdown across 12 of the 15 Scope 3 categories defined by the GHG Protocol, matching the level of disclosure in 2024, demonstrating consistent Scope 3 emissions reporting coverage year over year.a
In 2025, SCHOTT Pharma AG & Co reported total Scope 3 emissions of 412,948 metric tons of CO₂ equivalent (tCO₂e).a
Approximately 71.58% of these emissions originated from upstream activities such as purchased goods and capital goods, while 28.42% came from downstream activities like product use, distribution, and end-of-life treatment.a
Since 2023, SCHOTT Pharma AG & Co's Scope 3 emissionshave remained relatively stable, indicating that SCHOTT Pharma AG & Co's emissions have plateaued with no significant change in its value chain footprint.ab
Compared to the previous year (2024), SCHOTT Pharma AG & Co's Scope 3 emissions remained relatively stable, indicating that SCHOTT Pharma AG & Co's emissions have plateaued with no significant change in its value chain footprint.a
In 2025, SCHOTT Pharma AG & Co reported emissions for 12 out of the 15 Scope 3 categories defined by the GHG Protocol.a
This reflects a high level of granularity and transparency in the company's emissions reporting.
In 2025, the largest contributors to SCHOTT Pharma AG & Co's Scope 3 emissions were:a
In 2025, SCHOTT Pharma AG & Co reported Scope 1 greenhouse gas (GHG) emissions of 29,773 tCO₂e and total revenues of USD 1,157 millions. This translates into an emissions intensity of 25.73 tCO₂e per millions USD.a
In 2025, SCHOTT Pharma AG & Co reported a Scope 1 emissions intensity of 25.73 tCO₂e per millions USD. Compared to the peer group median of 3.58, this places the company above its industry benchmark, indicating it is less carbon-efficient than most competitors.a
In 2025, SCHOTT Pharma AG & Co ranked 20 out of 24 companies in its industry peer group, based on Scope 1 emissions intensity (measured in tCO₂e per millions USD).a
This places SCHOTT Pharma AG & Co among the least efficient performers, with one of the highest emissions intensities in its sector.a
In 2025, SCHOTT Pharma AG & Co reported a total carbon footprint of 487,317 metric tons of CO₂ equivalent (tCO₂e) across Scope 1, Scope 2, and Scope 3 emissions. This represents a 3.86% increase compared to 2024, suggesting a rise in emissions across its operations or value chain.a
The largest contributor to SCHOTT Pharma AG & Co's total carbon footprint was Scope 3 emissions, accounting for 84.74% of the company's total carbon footprint, followed by Scope 2 emissions at 9.15%.a